| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |